Peptides that block human immunodeficiency virus and methods of use thereof
AssigneeSyntello Vaccine Development AB
InventorsAnders Vahlne, Bo Svennerholm, Lars Rymo, Peter Horal, Stig Jeansson
Life of this patent
Estimating the term…
Abstract
It has now been found that relatively short peptides such as the tripeptide glycyl-prolyl-glycine are able to effectively inhibit HIV infection of cells and syncytia formation between HIV infected and and non-infected cells. The peptides are suitable for therapy of patients infected with HIV and in prevention of HIV infection.
Claims7
A method of inhibiting human immunodeficiency virus infection of host cells and syncytia formation between infected and non-infected cells, comprising administering to said cells an effective amount of a polypeptide having a C-terminal amide group of the molecular formula:
- ##STR3## wherein X is selected from the group consisting of hydrogen and about one to four additional amino acid residues.
A composition for inhibiting human immunodeficiency virus infection of host cells and syncytia formation between infected and non-infected cells, comprising an effective amount of a polypeptide having a C-terminal amide group of the molecular formula:
- ##STR4## wherein X is selected from the group consisting of hydrogen and about one to four additional amino acid residues.
An isolated peptide having the following molecular formula:
- ##STR5## wherein X is selected from the group consisting of glycine, arginyl-glycine, tyrosyl-arginyl-glycine.
Dependencies are inferred from the claim text.